Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 20/07/2024 am IST 5-day change 1st Jan Change
13.58 USD -0.37% Intraday chart for Stoke Therapeutics, Inc. -4.70% +158.17%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to Russell Microcap Growth Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell Microcap Value Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 3000E Value Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 3000 Value Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 2500 Value Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell Small Cap Comp Value Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to Russell 3000 Growth Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 2000 Value Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to Russell 3000E Growth Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to Russell 2000 Growth Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to Russell 2500 Growth Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to Russell Small Cap Comp Growth Index CI
Stoke Therapeutics, Inc.(NasdaqGS:STOK) added to S&P Biotechnology Select Industry Index CI
Dr. Huw Nash Steps Down as Chief Operating Officer of Stoke Therapeutics, Inc CI
Stoke Therapeutics Files Registration Statement For Sale of 10.8 Million Shares by Stockholders MT
Certain Pre-Funded Warrants of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Certain Common Stock of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing MT
Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating MT
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M MT
Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Stoke Therapeutics Appoints Thomas Leggett CFO MT
Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024 CI
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer CI
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Chart Stoke Therapeutics, Inc.
More charts
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.58 USD
Average target price
22.14 USD
Spread / Average Target
+63.05%
Consensus
  1. Stock Market
  2. Equities
  3. STOK Stock
  4. News Stoke Therapeutics, Inc.
  5. Stoke Therapeutics Files Registration Statement For Sale of 10.8 Million Shares by Stockholders